We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Direct oral anticoagulant use and risk of severe COVID‐19.
- Authors
Flam, B.; Wintzell, V.; Ludvigsson, J. F.; Mårtensson, J.; Pasternak, B.
- Abstract
Background: Hypercoagulability and thromboembolism are prominent features of severe COVID‐19, and ongoing anticoagulant use might be protective. Methods: We conducted a nationwide register‐based cohort study in Sweden, February through May, 2020, to assess whether ongoing direct oral anticoagulant (DOAC) use was associated with reduced risk of hospital admission for laboratory‐confirmed COVID‐19, or a composite of intensive care unit (ICU) admission or death due to laboratory‐confirmed COVID‐19. Results: DOAC use (n = 103 703) was not associated with reduced risk of hospital admission for COVID‐19 (adjusted hazard ratio [aHR] [95% confidence interval] 1.00 [0.75–1.33] vs. nonuse atrial fibrillation comparator [n = 36 875]; and aHR 0.94 [0.80–1.10] vs. nonuse cardiovascular disease comparator [n = 355 699]), or ICU admission or death due to COVID‐19 (aHRs 0.76 [0.51–1.12], and 0.90 [0.71–1.15], respectively). Conclusion: Ongoing DOAC use was not associated with reduced risk of severe COVID‐19, indicating that prognosis would not be modified by early outpatient DOAC initiation.
- Subjects
SWEDEN; COVID-19; ATRIAL fibrillation; INTENSIVE care units; ANTICOAGULANTS
- Publication
Journal of Internal Medicine, 2021, Vol 289, Issue 3, p411
- ISSN
0954-6820
- Publication type
Article
- DOI
10.1111/joim.13205